English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168625
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

AuthorsPaiva, Bruno; Cedena, Maria-Teresa; Puig, Noemi; Arana, Paula; Vidriales, Maria Belén; Cordon, Lourdes; Flores-Montero, Juan; Gutiérrez, Norma Carmen; Martín-Ramos, María-Luisa; Martínez-López, Joaquín; Ocio, Enrique M. CSIC ORCID ; Hernandez, Miguel T.; Teruel, Ana-Isabel; Rosiñol, Laura; Echeveste, María-Asunción; Martínez, Rafael; Gironella, Mercedes; Oriol, Albert; Cabrera, Carmen; Martín, Jesús; Bargay, Joan; Encinas, Cristina; Gonzalez, Yolanda; Dongen, J. J. M. van; Orfao, Alberto CSIC ORCID ; Bladé, Joan; Mateos, Maria Victoria; Lahuerta, Juan José; San Miguel, Jesús F. CSIC ORCID
Issue Date2016
PublisherAmerican Society of Hematology
CitationBlood 127(25): 3165-3174 (2016)
AbstractThe value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients. Because an optimal balance between treatment efficacy and toxicity is of utmost importance in patients with elderly MM, sensitive MRD monitoring might be particularly valuable in this patient population. Here, we used second-generation 8-color multiparameter-flow cytometry (MFC) to monitor MRD in 162 transplant-ineligible MM patients enrolled in the PETHEMA/GEM2010MAS65 study. The transition from first- to second-generation MFC resulted in increased sensitivity and allowed us to identify 3 patient groups according to MRD levels: MRD negative (<10; n = 54, 34%), MRD positive (between <10 and ≥10; n = 20, 12%), and MRD positive (≥10; n = 88, 54%). MRD status was an independent prognostic factor for time to progression (TTP) (hazard ratio [HR], 2.7; P = .007) and overall survival (OS) (HR, 3.1; P = .04), with significant benefit for MRD-negative patients (median TTP not reached, 70% OS at 3 years), and similar poorer outcomes for cases with MRD levels between <10 and ≥10 vs ≥10 (both with a median TTP of 15 months; 63% and 55% OS at 3 years, respectively). Furthermore, MRD negativity significantly improved TTP of patients >75 years (HR, 4.8; P < .001), as well as those with high-risk cytogenetics (HR, 12.6; P = .01). Using second-generation MFC, immune profiling concomitant to MRD monitoring also contributed to identify patients with poor, intermediate, and favorable outcomes (25%, 61%, and 100% OS at 3 years, respectively; P = .01), the later patients being characterized by an increased compartment of mature B cells. Our results show that similarly to transplant candidates, MRD monitoring is one of the most relevant prognostic factors in elderly MM patients, irrespectively of age or cytogenetic risk.
URIhttp://hdl.handle.net/10261/168625
DOIhttp://dx.doi.org/10.1182/blood-2016-03-705319
Identifiersdoi: 10.1182/blood-2016-03-705319
e-issn: 1528-0020
issn: 0006-4971
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.